IMM 1.72% 28.5¢ immutep limited

reply from martin rogers re dubai release, page-38

  1. 2,977 Posts.
    lightbulb Created with Sketch. 481
    blackjack

    There is now a clear pathway to Phase III and regulatory approval. CVAC Phase IIb trial commenced in mid-2010 and it is now merging into an 800-patient Phase III, to be conducted mainly in Europe from mid-2011.

    Ordinarily a drug or medical device requires two Phase III trials before it can apply for FDA approval. However PRR guidance from the FDA is that CVac IIb and III trials will be sufficient for this product. We expect this Phase III to help put CVac on the market by 2014 or 2015.


    http://www.primabiomed.com.au/investor/analyst_reports_pdf/Prima20110519.pdf
 
watchlist Created with Sketch. Add IMM (ASX) to my watchlist
(20min delay)
Last
28.5¢
Change
-0.005(1.72%)
Mkt cap ! $413.9M
Open High Low Value Volume
29.0¢ 29.5¢ 28.0¢ $1.441M 5.001M

Buyers (Bids)

No. Vol. Price($)
6 102393 28.5¢
 

Sellers (Offers)

Price($) Vol. No.
29.0¢ 14707 1
View Market Depth
Last trade - 16.10pm 03/07/2024 (20 minute delay) ?
IMM (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.